Background: Few studies have examined whether high-responsiveness to antiplatelet therapy is associated with an increased risk of bleeding in patients receiving dual antiplatelet therapy.
ndividual variability in the response of platelets to antiplatelet therapy is a well-known phenomenon, and lowresponders have an increased risk of stent thrombosis or adverse cardiac events after percutaneous coronary intervention (PCI). 1-7 Although guidelines recommend that dual antiplatelet therapy should be continued for at least 12 months after the implantation of drug-eluting stents (DES), 8 a higher incidence of bleeding complications is associated with dual antiplatelet therapy than with aspirin monotherapy. 9 Growing evidence indicates that major bleeding has a strong impact on the survival of patients who have acute coronary syndromes (ACS) and/or undergo stent implantation. 10-14 However, few have examined whether high-responsiveness to antiplatelet therapy (ie, marked inhibition of platelet aggregation) is associated with an increased risk of bleeding in patients given dual antiplatelet therapy. The "gold standard" platelet aggregation test by light transmittance aggregometry is not performed routinely in the clinical setting because of several limitations, including high cost and the need for skilled technicians and high sample volumes. 15 Alternatively, however, whole blood platelet aggregation can be easily measured by the screen filtration method using WBA-neo ® (ISK Corp, Tokyo, Japan), which is a point-of-care assay of platelet function. 16, 17 The goal of this retrospective trial was to assess whether platelet reactivity before stenting correlates with the risks of bleeding complications and ischemic cardiac events in patients who receive dual antiplatelet therapy.
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Methods
Patients
Between June 2006 and June 2008, 184 consecutive patients with coronary artery disease (132 men; mean age, 68 years), were enrolled. They were scheduled to undergo elective implantation of a DES while receiving 100 mg/day of aspirin and the Japanese standard dose of a thienopyridine (200 mg/day of ticlopidine for at least 7 days or a 300-mg loading dose of clopidogrel followed by 75 mg/day for at least 1 day). Exclusion criteria were the continuous use of anticoagulant agents before PCI, baseline hemoglobin level <8 g/dl, or platelet count <100,000/mm 3 . The study protocol was approved by the Ethics Committee of Yokohama City University. Written informed consent was given by all patients.
Laboratory Analyses
In the morning before PCI, peripheral venous blood samples were drawn using a 21G needle and added to a test tube containing a final concentration of 0.313% sodium citrate. Whole blood samples were kept at room temperature for 1 h, and thereafter platelet aggregation activity in response to adenosine diphosphate was measured by the screen filtration pressure method with WBA-neo ® . Aggregation reactions were started by adding 4 or 5 different concentrations of adenosine diphosphate (2, 4, 8, 16 , and 32 μmol/L if needed) to whole blood in test tubes, while constantly stirring at 37°C. Five minutes after stimulation, the absorbing pressure was measured through a microsieve with 30×30-μm holes. The estimated adenosine diphosphate concentration resulting in 50% filter blockage by platelet aggregation was calculated and defined as the platelet aggregation threshold index (PATI). Unfortunately, there is no consensus on the definition of highresponders or low-responders derived by this method. Because thienopyridine responsiveness is normally distributed, 18 and low-responders have been defined as the upper quartile of platelet reactivity in some previous studies, 1-3,7 in the present study the 1 st quartile was defined as high-responders, and the 4 th quartile as low-responders; the remaining patients were defined as middle-responders.
Renal insufficiency was defined as an estimated glomerular filtration rate <60 (ml · min -1 · 1.73 m −2 ). Anemia was defined as a baseline hemoglobin level <13 g/dl in men and <12 g/dl in women. Creatine kinase (CK) and CK-MB isoenzyme were measured 18 h after PCI in all subjects to decide whether they had periprocedural myocardial infarction. However, we did not measure the levels of troponin T or I in this study.
Coronary Angiography
All coronary angiograms were evaluated by a single cardiologist who was blinded to all other clinical data. Stenosis was considered significant if the lumen diameter was narrowed by ≥75% in the left anterior descending artery, left circumflex artery, or right coronary artery. Left main disease was diagnosed if the lumen diameter of the left main artery was narrowed by ≥50%.
Clinical Outcomes
All patients were required to receive dual antiplatelet therapy for at least 12 months after stent implantation. Follow-up visits were conducted for at least 12 months and those who became unable or unwilling to come back to the hospital were contacted by telephone. Similar to recent trials such as REPLACE-2, 13 non-coronary artery bypass grafting (CABG)-related major bleeding was defined as symptomatic intra- Values are percentages or mean ± SD. † Anemia was defined as baseline hemoglobin <13 g/dl in men and <12 g/dl in women. *Renal insufficiency was defined as estimated glomerular filtration rate <60 (ml · min -1 · 1.73 m -2 ). ACS, acute coronary syndrome; PCI, percutaneous coronary intervention.
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cranial hemorrhage, intraocular hemorrhage, retroperitoneal hemorrhage, overt bleeding resulting in a decrease in hemoglobin >3 g/dl, or bleeding requiring transfusion of at least 2 units of red blood cells. Adverse cardiac events were defined as cardiovascular death, ACS, target vessel revascularization, or non-target vessel revascularization. Myocardial infarction was defined as prolonged chest pain occurring at rest in association with characteristic ECG findings, as confirmed by an elevation of CK-MB isoenzyme to more than twice the upper limit of normal. Definite stent thrombosis was defined according to the Academic Research Consortium criteria. 19 Net clinical outcomes were defined as the sum of major bleeding and adverse cardiac events.
Statistical Analysis
Categorical variables were reported as percentages and compared by the chi-square test. Continuous variables were reported as means ± SD and compared by Student's t-test or 1-factor analysis of variance. P<0.05 was considered to indicate statistical significance. Event-free rates from the time of PCI were estimated by the Kaplan-Meier method and compared by log-rank test. Potential predictors with P values <0.20 on univariate analysis were included in multivariate logistic regression analysis. Odds ratios and 95% confidence intervals were calculated. Data were analyzed with SPSS 17 (SPSS, Inc, Chicago, IL, USA).
Results
Baseline Characteristics
All subjects were classified into 3 groups according to the extent of suppression of platelet reactivity: the 1 st quartile group (PATI >28 μmol/L) was classified as high-responders (n=46), the 2 nd and 3 rd quartile groups were classified as middle-responders (n=92), and the 4 th quartile group (PATI <6.3 μmol/L) was classified as low-responders (n=46). Except for the incidence of ACS on admission, there were no significant differences in patient characteristics, including age, sex, body weight, concomitant disease, and use of the femoral artery as an access site, among the 3 groups ( Table 1) .
Antiplatelet Therapy
Although the rate of receiving clopidogrel was lower and the duration of thienopyridine treatment before PCI was longer in the middle-and high-responders than in the low-responders, approximately 90% of patients in each group had received thienopyridine therapy for at least 7 days. The percentages of patients who were receiving other agents were similar among the 3 groups. Almost all patients (96%) had received dual antiplatelet therapy for at least 12 months after stent implantation, and the average duration of dual antiplatelet therapy was 14 months. One patient was non-compliant, and thienopyridine was discontinued and replaced by cilostazol in 6 patients because of adverse effects such as leukocytopenia or liver dysfunction ( Table 2 ). All patients continued to receive aspirin during the study period, except for the non-compliant patient.
Clinical Outcomes
No patients were lost to follow-up. Non-CABG-related major bleeding occurred in 12 patients (6.5%): 6 patients had gastrointestinal bleeding, 2 had urinary tract bleeding, and the other 4 had procedure-induced hemorrhage. Symptomatic intracranial or intraocular hemorrhage did not occur. All 12 patients were receiving dual antiplatelet therapy when they had major bleeding. Half of all major bleeding events occurred within 10 days after PCI, including procedure-induced hemorrhage. The incidence of major bleeding was significantly higher in high-responders than in middle-and low-responders during an average of 16 months follow-up (15 vs 4, 2%, P= 0.02) (Figure 1, Table 3 ). Patients with major bleeding had a higher rate of PATI >28 μmol/L than those without major bleeding (50 vs 23%, P=0.03). On multivariate logistic regression analysis, PATI >28 μmol/L was an independent predictor of major bleeding (odds ratio 4.26, 95% confidence interval 1.09-16.67, P=0.03) ( Table 4 ). The receiver-operating-characteristic curve indicated that a high-response predicted the occurrence of major bleeding (area under the curve 0.675, 95% confidence interval 0.521-0.830, P=0.04). Adverse cardiac events, including cardiovascular death, ACS, target vessel revascularization, and non-target vessel TSUKAHARA K et al.
revascularization, were less frequent in middle-responders than in low-responders (16 vs 37%, P=0.001); however, there was no significant difference in the incidence of adverse cardiac events between middle-and high-responders (16 vs 24%, P=0.16) (Figure 2) . Definite stent thrombosis did not occur in any patient. Only 4 high-responders had both major bleeding and an adverse cardiac event during the follow-up period. Middle-responders were superior to high-and lowresponders with respect to net clinical outcomes (21 vs 39, 39%, P=0.02) ( Table 3) .
Discussion
Guidelines for PCI recommend that dual antiplatelet therapy should be given for at least 12 months after the implantation of DES in patients who are not at high risk for bleeding. Values are percentages. *Adverse cardiac events were defined as cardiovascular death, ACS, target vessel revascularization, or non-target vessel revascularization. † Major bleeding (non-CABG-related) was defined as symptomatic intracranial hemorrhage, intraocular hemorrhage, retroperitoneal hemorrhage, overt bleeding resulting in a decrease in hemoglobin >3 g/dl, or bleeding requiring transfusion of > -2 units of red blood cells. ‡ Net clinical outcomes were defined as the sum of major bleeding and adverse cardiac events. CABG, coronary artery bypass graft surgery; ACS, acute coronary syndrome. 
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On the other hand, the incidence of bleeding complications is higher in patients given dual antiplatelet therapy than in those given aspirin monotherapy. 9 Because excessive doses of anticoagulants are associated with an increased risk of major bleeding, determining the adequate intensity of anticoagulation is particularly important for patients with a high risk of bleeding. 20 However, few studies have examined the relationship between high-responsiveness to antiplatelet therapy and an increased risk of bleeding in patients given dual antiplatelet therapy. Among patients who undergo CABG after recently receiving clopidogrel, preoperative testing of platelet function can identify those at highest risk for perioperative bleeding and transfusions. 21 One case report suggested a potential link between high-responsiveness to dual antiplatelet therapy and post-PCI fatal intracranial bleeding. 22 In other reports, a high-response to antiplatelet therapy was not significantly associated with severe bleeding events, 23 but was a strong predictor of minor bleeding episodes in recent studies. 24 Our trial is the first to clearly show that highresponsiveness to antiplatelet therapy is associated with an increased risk of non-CABG-related major bleeding. We should be concerned about the importance of antiplatelet therapy monitoring, and tailored therapy might minimize both ischemic and bleeding risks. Decreasing the dose of thienopyridine may lead to a lower rate of major bleeding in highresponders, but firm evidence supporting clear-cut treatment recommendations is lacking. A growing body of evidence suggests that major bleeding has a strong impact on the survival of patients with ACS and/or who undergo PCI. A recent study has shown that major bleeding is a powerful independent predictor of 30-day mortality in patients with ACS managed invasively. 12 Other studies demonstrate a strong relation between major bleeding within 30 days and 1-year mortality after PCI. 13, 14 Moreover, prasugrel, a 3 rd -generation thienopyridine, produces greater inhibition of platelet aggregation than clopidogrel. 25, 26 The development of prasugrel may shift attention to the increased risk of bleeding rather than the prevention of ischemic events, so net clinical outcomes based on both ischemic events and bleeding complications have been assessed in recent clinical trials, such as TRITON-TIMI 38 26 and HORIZONS-AMI. 27 We need to consider the balance between ischemic events and bleeding risk in patients undergoing PCI. 28, 29 In the REPLACE-2 trial, which was a double-blind, activecontrolled study, major bleeding occurred in 3.2% of patients. 13 The rate of major bleeding during an average of 16 months follow-up was not as low (6.5%) in the present study, most likely because patients at increased risk for bleeding were not excluded from this "real world" cohort study.
Previous studies have reported that low-responders who receive clopidogrel therapy and undergo elective PCI are at increased risk for post-procedural ischemic events, and lowresponsiveness is an independent predictor of stent thrombosis. 3-7 Stent thrombosis is known to occur less frequently in Asian patients than in Caucasians. [30] [31] [32] In the present study, low-responders were more likely to have adverse cardiac events as reported previously, but stent thrombosis did not occur. In fact, the difference in ischemic events was mainly driven by the rate of non-target vessel revascularization. This result may be attributed to a pan-coronary process that reflects the higher incidence of ACS in low-responders. Although the frequency of major bleeding was significantly higher in high-responders than in middle-responders, there was no significant difference in the incidence of adverse cardiac events between these 2 groups. Consequently, net clinical outcomes were better in middle-responders than in high-or low-responders, whereas there were no significant differences in the patient characteristics of the 3 groups. Our results suggest that optimization of antiplatelet therapy by platelet-function monitoring might contribute to the prevention of ischemic events and bleeding complications.
In the present study, whole blood aggregation was measured by the screen filtration pressure method with WBA-neo ® . This machine permits one of the point-of-care assays of platelet function. It is easy to use in daily clinical practice and can measure whole blood aggregation without centrifugation of blood. Platelet aggregation with this method correlates with the results of light transmission aggregation. 33 In the future, the clinical benefits of point-of-care assays must be confirmed in prospective studies. 34-36
Study Limitations
First, it was performed at a single center and had a small Figure 2 . Event-free rates according to the post-treatment platelet reactivity before stenting. Adverse cardiac events were defined as death, acute coronary syndromes, target vessel revascularization, or non-target vessel revascularization.
TSUKAHARA K et al. sample size. Further prospective studies are needed to estimate the risks of bleeding and ischemic events associated with high-responsiveness to antiplatelet therapy. Second, most subjects received ticlopidine, because in Japan clopidogrel is approved for use in only patients with non-ST elevation ACS. However, both drugs are adenosine diphosphate receptor antagonists, and responsiveness to either clopidogrel or ticlopidine follows a normal distribution with similar rates of low-responders. 18 Third, the rate of usage of clopidogrel was higher in low-responders than in the other 2 groups, possibly because of the slightly higher incidence of ACS in low-responders. Among 345 patients who received dual antiplatelet therapy for at least 14 days, there was no difference between the rate of low-responders with PATI <6.3 μmol/L in patients treated with 75 mg/day of clopidogrel (20%) and those treated with 200 mg/day of ticlopidine (17%) (data not shown). Fourth, platelet function testing was performed only once before PCI. Recent studies provide evidence that posttreatment platelet reactivity before PCI is a better estimate of thrombotic risk than baseline platelet reactivity or the difference between baseline and post-treatment reactivity. 2, 37 Pretreatment analysis of baseline platelet reactivity is not suitable for daily clinical practice, because most patients with ACS are treated urgently, and many others are already receiving chronic thienopyridine therapy on admission to the hospital.
Conclusions
Low-responders to dual antiplatelet therapy were more likely to have adverse cardiac events, as reported previously. However, in the present study the difference in ischemic events was mainly driven by the rate of non-target vessel revascularization. In contrast, high-responders had a higher rate of bleeding complications with no reduction in adverse cardiac events as compared with middle-responders. The measurement of pre-PCI platelet reactivity may be useful for risk stratification according to adverse cardiac events and bleeding complications in patients who receive DES and are treated with dual antiplatelet therapy.
